GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more

Location: 1525 O’Brien Drive, Menlo Park, CA, 94025, United States | Website: https://grail.com | Industry: Diagnostics & Research | Sector: Healthcare


Market Cap

1.465B

52 Wk Range

$12.33 - $63.99

Previous Close

$43.39

Open

$42.65

Volume

768,369

Day Range

$40.30 - $42.82

Enterprise Value

1.239B

Cash

674.6M

Avg Qtr Burn

-116.2M

Insider Ownership

14.18%

Institutional Own.

66.50%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date